Evidence map›Paper›PMID 37524969›Full record

ArticleNature structural & molecular biology2023

Molecular basis for nuclear accumulation and targeting of the inhibitor of apoptosis BIRC2.

Adam H Tencer, Yucong Yu, Sebastien Z Causse, Grant R Campbell, Brianna J Klein, Hongwen Xuan, Jessy Cartier, Mark A Miles, Nitika Gaurav, Aymeric Zadoroznyj and 7 more

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Adam H Tencer *Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.
Yucong Yu *Department of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA.
Sebastien Z Causse *Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231, Dijon, France and Université de Bourgogne Franche-Comté, Dijon, France.
Grant R Campbell *Division of Infectious Diseases, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3927-1994
Brianna J KleinDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID http://orcid.org/0000-0003-2479-8013
Hongwen XuanDepartment of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA.
Jessy CartierInstitut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231, Dijon, France and Université de Bourgogne Franche-Comté, Dijon, France.
Mark A MilesDepartment of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia.ORCID http://orcid.org/0000-0002-2162-2939
Nitika GauravDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.
Aymeric ZadoroznyjInstitut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231, Dijon, France and Université de Bourgogne Franche-Comté, Dijon, France.
Tina A HoltDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID http://orcid.org/0000-0003-3027-4478
Hong WenDepartment of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA.ORCID http://orcid.org/0000-0001-8739-4572
Christine J HawkinsDepartment of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia.ORCID http://orcid.org/0000-0001-8120-1071
Stephen A SpectorDivision of Infectious Diseases, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA. saspector@health.ucsd.edu.ORCID http://orcid.org/0000-0002-1882-4855
Laurence DubrezInstitut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231, Dijon, France and Université de Bourgogne Franche-Comté, Dijon, France. laurence.dubrez@u-bourgogne.fr.ORCID http://orcid.org/0000-0002-7030-2181
Xiaobing ShiDepartment of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA. xiaobing.shi@vai.org.ORCID http://orcid.org/0000-0001-5242-8189
Tatiana G KutateladzeDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA. tatiana.kutateladze@cuanschutz.edu.ORCID http://orcid.org/0000-0001-7375-6990
Inserm · FRUniversity of Colorado Denver · USVan Andel Institute · USLa Trobe University · AUUC San Diego Health System · USUniversity of Colorado Anschutz Medical Campus · USUniversity of South Dakota · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Nanopeptide Targeting of HIV-CNS Reservoirs without ReactivationR01NS104015 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SPECTOR, STEPHEN A · 2017 to 2021
$2.9M
Targeting acetylated histone H4 by MLL4R01AG067664 · NIA · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2021 to 2025
$2.1M
Role of GAS41 in Human CancerR01CA204020 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI SHI, XIAOBING · 2016 to 2020
$2.0M
Targeting HIV Myeloid Reservoirs in the CNS by IAP and TREM1 InhibitionR01MH128021 · NIMH · UNIVERSITY OF SOUTH DAKOTA · PI CAMPBELL, GRANT R · 2021 to 2025
$1.9M
Molecular analysis of ASH1LR01CA252707 · NCI · UNIVERSITY OF COLORADO DENVER · PI TATIANA G KUTATELADZE · 2020 to 2026
$1.9M
The role of JADE in HBO complexesR01HL151334 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.8M
Discovery of small molecules targeting the histone acetylation reader ENLR01CA255506 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI WEN, HONG · 2021 to 2024
$1.7M
High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation ReaderR01CA268440 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI SHI, XIAOBING · 2022 to 2025
$1.7M
Epigenetic mechanisms for regulation of p300R01GM135671 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.4M
NCI NIH HHS R01 CA204020NCI NIH HHS R01 CA252707NCI NIH HHS R01 CA255506NCI NIH HHS R01 CA268440NHLBI NIH HHS R01 HL151334NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI106716NIA NIH HHS R01 AG067664NIA NIH HHS R56 AG067664NIGMS NIH HHS R01 GM125195NIGMS NIH HHS R01 GM135671NIMH NIH HHS R01 MH128021NINDS NIH HHS R01 NS104015
6 · The paper itself

Abstract

The inhibitor of apoptosis protein BIRC2 regulates fundamental cell death and survival signaling pathways. Here we show that BIRC2 accumulates in the nucleus via binding of its second and third BIR domains, BIRC2

Indexed as

Inhibitor of Apoptosis ProteinsThiazolesApoptosisHumansSignal TransductionUbiquitin-Protein LigasesBIRC2 protein, humanInhibitor of Apoptosis ProteinsLCL161ThiazolesUbiquitin-Protein Ligases

Identifiers

PMID37524969
PMCPMC10702411
OpenAlexW4385415867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.